240 related articles for article (PubMed ID: 17670863)
21. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358
[TBL] [Abstract][Full Text] [Related]
22. Effects of early overnutrition on the renal response to Ang II and expression of RAAS components in rat renal tissue.
Granado M; Amor S; Fernández N; Carreño-Tarragona G; Iglesias-Cruz MC; Martín-Carro B; Monge L; García-Villalón AL
Nutr Metab Cardiovasc Dis; 2017 Oct; 27(10):930-937. PubMed ID: 28958692
[TBL] [Abstract][Full Text] [Related]
23. Role of angiotensin AT2 receptors and nitric oxide in the cardiopulmonary baroreflex control of renal sympathetic nerve activity in rats.
Abdulla MH; Johns EJ
J Hypertens; 2013 Sep; 31(9):1837-46. PubMed ID: 23751965
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver.
Herath CB; Mak K; Burrell LM; Angus PW
Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G99-108. PubMed ID: 23086915
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Abadir PM; Carey RM; Siragy HM
Hypertension; 2003 Oct; 42(4):600-4. PubMed ID: 12953015
[TBL] [Abstract][Full Text] [Related]
26. Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release.
Stegbauer J; Kuczka Y; Vonend O; Quack I; Sellin L; Patzak A; Steege A; Langnaese K; Rump LC
Am J Physiol Regul Integr Comp Physiol; 2008 Feb; 294(2):R421-8. PubMed ID: 18046021
[TBL] [Abstract][Full Text] [Related]
27. Early co-expression of cyclooxygenase-2 and renin in the rat kidney cortex contributes to the development of N(G)-nitro-L-arginine methyl ester induced hypertension.
Guzmán-Hernández EA; Villalobos-Molina R; Sánchez-Mendoza MA; Del Valle-Mondragón L; Pastelín-Hernández G; Ibarra-Barajas M
Can J Physiol Pharmacol; 2015 Apr; 93(4):299-308. PubMed ID: 25761067
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide and cGMP mediate alpha1D-adrenergic receptor-Stimulated protein secretion and p42/p44 MAPK activation in rat lacrimal gland.
Hodges RR; Shatos MA; Tarko RS; Vrouvlianis J; Gu J; Dartt DA
Invest Ophthalmol Vis Sci; 2005 Aug; 46(8):2781-9. PubMed ID: 16043851
[TBL] [Abstract][Full Text] [Related]
29. Exercise training attenuates angiotensin II-induced vasoconstriction in the aorta of normotensive but not hypertensive rats.
Oliveira PR; Oliveira PB; Rossignoli PS; Spadella MA; Chies AB
Exp Physiol; 2020 Apr; 105(4):732-742. PubMed ID: 31999028
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide synthase and renin-angiotensin gene expression and NOS function in the postnatal renal resistance vasculature.
Ratliff B; Rodebaugh J; Sekulic M; Dong KW; Solhaug M
Pediatr Nephrol; 2009 Feb; 24(2):355-65. PubMed ID: 18836750
[TBL] [Abstract][Full Text] [Related]
31. Systemic Aldosterone, But Not Angiotensin II, Plays a Pivotal Role in the Pathogenesis of Renal Injury in Chronic Nitric Oxide-Deficient Male Rats.
Suehiro T; Tsuruya K; Ikeda H; Toyonaga J; Yamada S; Noguchi H; Tokumoto M; Kitazono T
Endocrinology; 2015 Jul; 156(7):2657-66. PubMed ID: 25872005
[TBL] [Abstract][Full Text] [Related]
32. Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Abdel-Rahman EM; Abadir PM; Siragy HM
Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1473-8. PubMed ID: 18799632
[TBL] [Abstract][Full Text] [Related]
33. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Awad AS; Webb RL; Carey RM; Siragy HM
J Hypertens; 2004 Aug; 22(8):1571-7. PubMed ID: 15257181
[TBL] [Abstract][Full Text] [Related]
34. AT2-antagonist sensitive potentiation of angiotensin II-induced vasoconstrictions by blockade of nitric oxide synthesis in rat renal vasculature.
Muller C; Endlich K; Barthelmebs M; Helwig JJ
Br J Pharmacol; 1997 Dec; 122(7):1495-501. PubMed ID: 9421301
[TBL] [Abstract][Full Text] [Related]
35. Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension.
Rincón J; Correia D; Arcaya JL; Finol E; Fernández A; Pérez M; Yaguas K; Talavera E; Chávez M; Summer R; Romero F
Life Sci; 2015 Mar; 124():81-90. PubMed ID: 25623850
[TBL] [Abstract][Full Text] [Related]
36. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape.
Hu L; Sealey JE; Chen R; Zhou Y; Merali C; Shi Y; Laragh JH; Catanzaro DF
Am J Hypertens; 2004 May; 17(5 Pt 1):395-403. PubMed ID: 15110897
[TBL] [Abstract][Full Text] [Related]
37. Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling.
Banday AA; Lokhandwala MF
Hypertension; 2008 Dec; 52(6):1099-105. PubMed ID: 18955661
[TBL] [Abstract][Full Text] [Related]
38. AT(1) receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats.
Hultström M; Helle F; Iversen BM
Am J Physiol Renal Physiol; 2009 Jul; 297(1):F163-8. PubMed ID: 19386725
[TBL] [Abstract][Full Text] [Related]
39. Production and role of extracellular guanosine cyclic 3', 5' monophosphate in sodium uptake in human proximal tubule cells.
Sasaki S; Siragy HM; Gildea JJ; Felder RA; Carey RM
Hypertension; 2004 Feb; 43(2):286-91. PubMed ID: 14718358
[TBL] [Abstract][Full Text] [Related]
40. Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury.
Pojoga LH; Yao TM; Opsasnick LA; Siddiqui WT; Reslan OM; Adler GK; Williams GH; Khalil RA
J Pharmacol Exp Ther; 2015 Oct; 355(1):32-47. PubMed ID: 26183312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
